Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-02 08:20:22 - browse：67

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

entertainment

WSS

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

NIH trials fail to test meaningful long Covid therapies, experts say

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Naloxone nonprofit donates 200,000 doses after FDA approval

In key trial, Verve's treatment lowers cholesterol levels in patients

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

hotspot

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

In age of alternative facts, a scholarly course on calling out crap

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Dobbs anniversary: the lost opportunity of abortion as health care

A daunting task: navigating dual Medicare, Medicaid eligibility

Medical leaders decry Supreme Court decision on affirmative action

Gain of function research would be limited under House proposal

Walensky prepares to leave CDC — and Congress — behind

Gain of function research would be limited under House proposal

United colonoscopy coverage change 'may cost lives,' doctors say

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

focus

Readout LOUD podcast: A CRISPR milestone, biotech mixology

The best solution to the drug shortages problem

Drastic changes should bring profitability, startup health insurers say

South Korea throws huge K

Methadone doses haven’t kept up in the age of fentanyl

Weight loss drug costs may need more research, senator suggests

entertainment

entertainment

explore

explore